Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 14.

Journal Article

Bosse, Autoren K., Faust, U., Gruber, I, Habhab, W., Guenther, G., Siebers-Renelt, U., Kiechle, M., Speiser, D., Dikow, N., Kast, K., Arnold, N., Vesper, A-S, Harbeck, N., Briest, S., Thomssen, C., Gehrig, A., Wallaschek, H., Solbach, C., Wolf, M., Witzel, I, Holzhauser, I, Kaulfuss, S., Janni, W., Engel, C., Riess, O., Schmutzler, R. and Schroeder, C. (2020). Clinical-pathological Characterization of 1078 Advice Seekers with pathogenic CHEK2 Mutation from the German Consortium of Familial Breast and Ovarian Cancer (DK-FBREK). Geburtshilfe Frauenheilkd., 80 (6). S. E23 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Degenhardt, T., Gluz, O., Thomssen, C., Vetter, M., Kates, R., Warm, M., Shak, S., Augustin, D., Kusche, M., Untch, M., Paepke, S., Uleer, C., Duennebacke, J., Nitz, U. and Harbeck, N. (2010). Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezal, M., Baler, B., Baake, G., Kolberg, H. -C, Guggenberger, M., Warm, N., Harbeck, N., Wuerstlein, R., Deuker, J. -U, Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W, Breitbach, G. -P, Janni, W., Landthaler, R., Kohls, A., Rezek, D., Nosslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Kuemmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischice, E. -M, Beckmann, M. W. and Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd., 74 (12). S. 1137 - 1144. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Giuz, O., Kreipe, H., Degenhardt, T., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2011). Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, O., Kreipe, H. H., Kates, R. E., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2012). Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Habhab, W., Faust, U., Guenther, G., Siebers-Renelt, U., Kiechle, M., Ott, C., Dikow, N., Kast, K., Vesper, A., Solbach, C., Harbeck, N., Stiller, M., Gehrig, A., Thomssen, C., Wallaschek, H., Arnold, N., Holzhauser, I., Kaulfuss, S., Volk, A., Janni, W., Engel, C., Schmutzler, R., Riess, O., Schroeder, C. and Bosse, K. (2020). Clinical and molecular characterization of 1253 carriers of a deleterious CHEK2 mutation from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Eur. J. Hum. Genet., 28 (SUPPL 1). S. 93 - 95. LONDON: SPRINGERNATURE. ISSN 1476-5438

Hack, C. C., Haeberle, L., Brucker, S. Y., Janni, W., Volz, B., Loehberg, C. R., Hartkopf, A. D., Walter, C-B, Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., Hoffmann, O., Kuemmel, S., Martin, B., Thomssen, C., Graf, H., Wolf, C., Lux, M. P., Bayer, C. M., Rauh, C., Almstedt, K., Gass, P., Heindl, F., Brodkorb, T., Willer, L., Lindner, C., Kolberg, H-C, Krabisch, P., Weigel, M., Steinfeld-Birg, D., Kohls, A., Brucker, C., Schulz, V, Fischer, G., Pelzer, V, Rack, B., Beckmann, M. W., Fehm, T., Rody, A., Maass, N., Hein, A., Fasching, P. A. and Nabieva, N. (2020). Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast, 50. S. 11 - 19. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Huober, J., Gluz, O., Hartmann, A., Kates, R., Kreipe, H. H., Pelz, E., Thomssen, C., Fischer, H. H., Moebus, V., Augustin, D., Weiss, E., Erber, R., Liedtke, C., Kuhn, W., Nitz, U. and Harbeck, N. (2010). Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer An Analysis of the WSG EC-Doc Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Jacobs, V. R., Kates, R., Kantelhardt, E. J., Vetter, M., Schmitt, M., Jaenicke, F., Untch, M., Thomssen, C. and Harbeck, N. (2010). Health Economic Impact of Risk Group Selection According to ASCO-Recommended Biomarkers uPA/PAI-1 in Node-Negative Primary Breast Cancer. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Maurer, C., Agostinetto, E., Ameye, L., Lambertini, M., Martel, S., Ponde, N. F., Brandao, M., Poggio, F., Ferreira, A. R., Schiff, R., De Angelis, C., Gelber, R. D., Dent, S., Thomssen, C., Piccart, M. and de Azambuja, E. (2022). Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial. Ann. Oncol., 33. S. S154 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Moebus, V., Diel, I. J., Harbeck, N., Elling, D., Jackisch, C., Thomssen, C., Untch, M., Conrad, B., Schneeweiss, A., Kreienberg, R., Huober, J., Mueller, V., Lueck, H-J, Bauerfeind, I., Loibl, S., Nekljudova, V. and von Minckwitz, G. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer 1st Interim Efficacy Analysis. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Nabieva, N., Fehm, T., Haeberle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Popovic, M., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Hack, C. C., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur. J. Cancer, 96. S. 82 - 91. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Nabieva, N., Kellner, S., Fehm, T., Haebrle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann. Oncol., 29 (1). S. 186 - 193. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Thu Mar 28 22:37:54 2024 CET.